Evidence map›Paper›PMID 41396384›Full record

ReviewInternational ophthalmology2025

Advances in the treatment of blinding retinal diseases.

Zhao Li, Siyan Jin, Wenjing Xu, Mengdi Zhang, Xiaoli Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhao LiOphthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China.
Siyan JinOphthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China.
Wenjing XuOphthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China.
Mengdi ZhangOphthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China.
Xiaoli LiuOphthalmologic Center of the Second Hospital, Jilin University, Ziqiang Street 218, Changchun, 130000, People's Republic of China. lpw_lxl@126.com.ORCID http://orcid.org/0000-0002-5793-1872

Funding

National Natural Science Foundation of China No. 82371043the Project of Outstanding Talents in Scientific and Technological Innovation and Entrepreneurship for Middle-aged and Young Scientists of Jilin Provincial Science and Technology Department No.20240601014RC
6 · The paper itself

Abstract

Blinding retinal diseases, including inherited and degenerative conditions, rank globally among the primary causes of permanent vision loss. While certain degenerative retinal diseases like age-related macular degeneration and diabetic retinopathy can be partially managed through intravitreal anti-VEGF injections or the use of complement inhibitors, most patients still lack effective treatment options. Recently, several promising therapeutic avenues have surfaced, such as stem cell-derived retinal pigment epithelium cell transplantation, gene therapy, and the implantation of retinal prostheses. This review summarizes recent clinical trials and advances in gene therapy for inherited retinal diseases, outlines techniques for retinal pigment epithelium cell transplantation, and discusses methods to improve graft survival. It also examines strategies for enhancing the resolution of retinal prostheses and explores their future clinical potential, providing new perspectives on the management of degenerative retinal conditions.

Indexed as

BlindnessGenetic TherapyRetinal DiseasesRetinal Pigment EpitheliumStem Cell TransplantationHumansGene therapyRetinal diseasesRetinal prosthesesStem therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.